Evidence map›Paper›PMID 42371623›Full record

ArticleJAMA network open2026

State Cost Growth Benchmark Programs and Total Medical Expenditures, 2010 to 2020.

Aleena Imran, Carlos Oronce, Nicholas Jackson, Ya-Chen Tina Shih, Cheryl L Damberg, Catherine Sarkisian, John N Mafi

Abstract read
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aleena ImranDivision of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
Carlos OronceDivision of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
Nicholas JacksonDepartment of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.
Ya-Chen Tina ShihDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Cheryl L DambergRAND, Santa Monica, California.
Catherine SarkisianDivision of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
John N MafiDivision of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.

Funding

Midcareer Award in Patient-Oriented Community-Academic Partnered Aging ResearchK24AG047899 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SARKISIAN, CATHERINE A · 2014 to 2025
$2.0M
NIA NIH HHS K24 AG047899
6 · The paper itself

Abstract

Importance: US health care spending continues to outpace economic growth, prompting states to implement cost-growth benchmark programs aimed at constraining expenditure growth. However, empirical evidence evaluating their associations with overall spending growth remains limited. Objective: To evaluate whether adoption of statewide cost-growth benchmark programs is associated with changes in per capita total medical expenditure (TME) growth. Design, Setting, and Participants: This cohort study used a quasi-experimental, difference-in-differences analysis with 2-way fixed effects to examine data from the Centers for Medicare & Medicaid Services State Health Expenditure Accounts from January 1, 2010, to December 31, 2020. A total of 561 state- and year-level observations across 50 states and Washington, DC, were analyzed. Statistical analysis was performed from January 2025 to April 2026. Exposures: Adoption of statewide cost-growth benchmark programs in Massachusetts (2013), Maryland (2014), Vermont (2018), Rhode Island (2019), and Delaware (2019); all states paired their benchmark programs with enforcement mechanisms and/or payment reforms except for Delaware, which relied solely on public reporting. Main Outcomes and Measures: The primary outcome was log-transformed per capita TME growth. Secondary outcomes included changes in payer-specific and spending category-specific expenditures. Results: Across all 50 states and Washington, DC, the mean annual per capita TME increased by 3.7% during the study period. Implementation of cost-growth benchmark programs was associated with a 2.0% reduction in TME growth (95% CI, -3.3% to -0.7%; P = .004). Reductions were observed in all treatment states except Delaware. Medicare spending growth decreased across all treatment states (-2.4%; 95% CI, -4.2 to -0.6; P = .009), whereas reductions in commercial spending growth were concentrated in Maryland (-2.2%; 95% CI, -3.6 to -0.8; P = .003) and Rhode Island (-18.3%; 95% CI, -20.3% to -16.2%; P < .001). Spending reductions were primarily driven by decreases in hospital (-5.3%; 95% CI, -7.3% to -3.3%; P < .001) and skilled nursing facility expenditures (-7.7%; 95% CI, -10.5% to -4.9%; P < .001), alongside concomitant spending increases in home health spending (8.9%; 95% CI, 3.2% to 14.8%; P = .002). Findings were robust to multiple sensitivity analyses. Conclusions and Relevance: This cohort study found that state cost-growth benchmark programs were associated with modest reductions in health care spending growth. These findings suggest that benchmark programs, particularly those paired with enforcement mechanisms or payment reforms, may contribute to slowing expenditure growth and shifting care toward lower-cost settings.

Indexed as

BenchmarkingHealth ExpendituresCohort StudiesHumansMedicareUnited States

Identifiers

PMID42371623
PMCPMC13316600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.